US EditionGenentech: Largest Real-World Studies Show Vabysmo’s Long-Term Benefits for Wet AMD, DME
Summary by Eyewire+
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Genentech: Largest Real-World Studies Show Vabysmo’s Long-Term Benefits for Wet AMD, DME
Genentech presented more than 20 abstracts across its ophthalmology portfolio at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting. Key studies highlight Vabysmo’s long-term ability to sustain vision improvements in patients with wet age-related diabetic macular edema (DME), retinal vein occlusion (RVO), and degeneration (AMD), and its capability to reduce treatment frequency. Notable studies presented at ARVO …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
